Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia

Viruses(2020)10.3390/v12050564Source: DataRank Database

An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia is a research paper published in Viruses (2020). On theSindex it has a DataRank of 0. It has been cited 33 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access33 citations

Download PDF

Cite:

Linked data & code

gen doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 3.01)OA: goldTopics (68)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Kaining Zhi ORCID,Prashanth K.B. Nagesh ORCID,Namita Sinha ORCID,Pallabita Chowdhury ORCID,Hao Chen ORCID

Live enrichment

PubMed:32443728 PMC:PMC7290679 OpenAlex:https://openalex.org/W3028065264

National Institutes of Health

Grant: DA047178

National Institutes of Health

Grant: CA174841

National Institutes of Health

Grant: CA213232

National Institutes of Health

Grant: S10OD016226

NCI NIH HHS

Grant: P30 CA008748

FWCI

3.01

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://www.mdpi.com/1999-4915/12/5/564/pdf?version=1590663633

GOLDhttps://www.mdpi.com/1999-4915/12/5/564/pdf?version=1590663633

publisherhttps://www.mdpi.com/1999-4915/12/5/564/pdf?version=1590663633

publisherhttps://www.mdpi.com/1999-4915/12/5/564/pdf

journalhttps://doi.org/10.3390/v12050564

Fields of Study

HIV Research and TreatmentNeuroinflammation and Neurodegeneration MechanismsHIV/AIDS Research and InterventionsMedicineChemistryAnimalsAnti-HIV AgentsAnti-Retroviral AgentsBlood-Brain BarrierDisease Models, AnimalDrug CarriersDrug Delivery SystemsHIV InfectionsHIV-1Integrase InhibitorsMacrophagesMaleMiceMice, Inbred NODMicrogliaNanoparticlesPilot ProjectsPlasmaQuinolonesViral LoadVirus Replication

MeSH Terms

AnimalsBlood-Brain BarrierDisease Models, AnimalDrug CarriersMacrophagesMalePilot ProjectsPlasmaVirus ReplicationQuinolonesHIV-1HIV InfectionsDrug Delivery SystemsMice, Inbred NODMicrogliaAnti-HIV AgentsIntegrase InhibitorsViral LoadAnti-Retroviral AgentsMiceNanoparticles

Keywords

MicrogliaElvitegravirPLGABlood–brain barrierViral replicationEndocytosisIn vitroBiologyVirologyPharmacologyImmunologyViral loadVirusCentral nervous systemInflammationBiochemistryAntiretroviral therapyNeuroscienceCellHIVNanomedicine

Sustainable Development Goals

SDG 0: Good health and well-being

An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia

FAIR Checklist

Authors (9)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)